Disclosed are vaccine compositions comprising a single KSHV-LP comprising two or more KSHV glycoproteins and/rl or one or more T cell antigens and methods of preventing or treating KSHV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more KSHV glycoproteins simultaneously to generate a vaccine comprising a single virus-like particle. The expression system may include a single plasmid inserted with two or more nucleic acid sequences that encode two or more KSHV glycoproteins linked by one or more linking sequences such that the KSHV glycoproteins are co-expressed simultaneously.

Vaccine compositions comprising a single KSHV-LP comprising two or more KSHV glycoproteins and/or one or more T cell antigens and methods of preventing or treating KSHV infections using the vaccine compositions. An expression system or a single expression vector for co-expressing two or more KSHV glycoproteins simultaneously to generate a vaccine comprising a single virus-like particle. The expression system may include a single plasmid inserted with two or more nucleic acid sequences that encode two or more KSHV glycoproteins linked by one or more linking sequences such that the KSHV glycoproteins are co-expressed simultaneously.

Vaccine compositions comprising a single KSHV-LP comprising two or more KSHV glycoproteins and/or one or more T cell antigens and methods of preventing or treating KSHV infections using the vaccine compositions. An expression system or a single expression vector for co-expressing two or more KSHV glycoproteins simultaneously to generate a vaccine comprising a single virus-like particle. The expression system may include a single plasmid inserted with two or more nucleic acid sequences that encode two or more KSHV glycoproteins linked by one or more linking sequences such that the KSHV glycoproteins are co-expressed simultaneously.